fda blenrep - Search News

Order byBest matchMost fresh

News

GSK’s Blenrep faces setback

Zacks Investment Research on M… · 1d

FDA Advisory Panel Votes Against Approval of GSK's Blenrep Combo

GSK plc GSK announced that the FDA’s Oncologic Drugs Advisory Committee (ODAC) has voted against the overall benefit/risk profile of the Blenrep (belantamab mafodotin-blmf) combination therapy at the proposed dosing regimen.

Continue reading

GlobalData on MSN · 23h

GSK’s Blenrep faces setback as FDA cancer committee votes against approval

· 1d · on MSN

FDA Committee Votes Against GSK Blood Cancer Drug Blenrep

1d

Bristol Myers’ Reblozyl falls short in Phase 3; Blenrep voted down by FDA panel

The anemia treatment missed its main goal in a myelofibrosis study. Meanwhile, Blenrep's return to the U.S. market may have ...

Pharmalittle: We’re reading about a GSK setback, another Sarepta gene therapy death, and more

In a surprise, a FDA advisory panel voted that risks tied to a GSK blood cancer drug called Blenrep outweighed the benefits ...

Fierce Pharma1d

FDA advisors spurn GSK's Blenrep comeback dreams on safety, trial concerns

On a quest to bring its multiple myeloma antibody-drug conjugate Blenrep back to the U.S. | Members of the FDA's Oncologic ...

FDA Votes Against Proposed Blenrep Treatment Combo’s for Multiple Myeloma

The FDA's Oncologic Drugs Advisory Committee has casted their votes on the utilization of certain treatments in the multiple ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results